-
January 31, 2022
NCCN Guidelines for Patients: Cervical Cancer Bookmark
George Lundberg, MDThe nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for cervical cancer.
.
-
April 12, 2021
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer Bookmark
George Lundberg, MDThe ASCO Post reports on new results from a clinical trial testing a combination of the drugs lenvatinib and pembrolizumab in people with advanced or recurrent endometrial cancer. The results show that, compared to standard chemotherapy, this drug combo improves both overall and progression-free survival—according to both statistical and clinical analysis.
.
SEE ALL

Hope S. Rugo, MD
UCSF Comprehensive Cancer Center
-
March 22, 2022
Immunotherapy Approvals Signal a Need for Molecular Testing in Endometrial Cancer Bookmark
George Lundberg, MDMolecular testing often guides choices of immunotherapy, as illustrated in this OncLive story about endometrial cancer.
.
-
March 22, 2022
Immunotherapy to Treat Cancer Bookmark
George Lundberg, MDImmunotherapy uses biological substances, such as your own immune system, to attack cancer cells. Learn more about immunotherapy from the National Cancer Institute.
.
SEE ALL
Some of the most promising new treatments for metastatic uterine cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.
-
October 8, 2020
Preliminary Results of Two Large Immune Therapy Studies Show Promise in Advanced Cervical Cancer Bookmark
George Lundberg, MDPress release from Ohio State University Wexner Medical Center curated by Contributing Editor George Lundberg, MD.
This press release outlines promising preliminary results from two phase 2 clinical trials testing the drug balstilimab alone or in combination with zalifrelimab.
.
-
August 26, 2019
CAR T-cell Therapy for HPV-Induced Metastatic Cervical Cancer Bookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology, selected by Editor in Chief George Lundberg, MD, who notes:
CAR T-cell therapy has been approved by the U.S. Food and Drug Administration (FDA) for certain hematologic malignancies. This early study demonstrates its effectiveness in human papillomavirus (HPV)-induced metastatic cervical cancer as well.
Go to full article published by the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
SEE ALL

Tony Blau, MD
University of Washington
Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.
-
October 14, 2019
Pediatric Palliative Care: A Specialty Comes of Age
For a child with cancer, palliative care can provide much-needed relief from stress and symptoms—for the patient and their family alike. Palliative care is given alongside cancer treatment, and is not synonymous with “end-of-life” care. In fact, anyone with a serious illness can benefit from palliative care, no matter their long-term outlook. Because of its importance for children with cancer, we are honored to… Read more »
-
August 11, 2021
Anxiety Before Each Chemotherapy Treatment Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: Pancreatic cancer patients share their experiences with pre-chemo anxiety and their personal strategies for overcoming it.
.
-
February 11, 2020
‘Impressed With Impact’ of Ketamine in Cancer Palliative Care Bookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
SEE ALL
Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.
-
April 13, 2022
Cancer Commons Adapts to Remain True to Our Mission
With:People facing advanced cancer come to Cancer Commons to ensure they have all the information they need to make their best-possible cancer care decisions. Here, Curious Dr. George asks our CFO & COO Shelley Frisbie about recent updates to our organization. Curious Dr. George: You have been the CFO of Cancer Commons for some time and recently added the COO title and duties to… Read more »
-
March 16, 2022
Cellular Aging and the Development of Cancer
With: Kaumudi Bhawe, PhDCancer is so often a disease of older people that a whole medical field, “oncogeriatrics,” exists to address the topic. Deeper understanding of the links between cancer and aging could lead to better treatments. Here, our Curious Dr. George asks Cancer Commons Clinical Scientist Kaumudi Bhawe, PhD, about the relationship between cancer and aging processes that occur in individual cells in our bodies—throughout our… Read more »
SEE ALL
The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.
-
February 20, 2021
COVID-19 Vaccination: The VOICE for Patients with Cancer Bookmark
George Lundberg, MDThis piece from the scientific journal Nature Medicine describes a new clinical trial studying vaccination against COVID-19 specifically in patients with cancer.
.
-
February 20, 2021
Patients with Cancer Less Likely to Enroll in Clinical Trials Due to COVID-19 Bookmark
George Lundberg, MDFewer patients with cancer may be willing to enter a clinical trial. This Cancer Network article explains why and offers solutions.
.
SEE ALL